Sana Biotechnology Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
14.4%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$0.59next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly101.1MTarget: Maintain sufficient capital to fund operations through key clinical readouts
Non-GAAP Quarterly Operating Cash Burn Quarterly37MTarget: Manage cash burn to optimize runway into 2027
Trailing Twelve Months Net Loss Annually-242MTarget: Reduce net loss through strategic portfolio prioritization and operational efficiency
Watch Items
- SC451 Investigational New Drug (IND) Application FilingTrigger: IND submission and FDA clearance to initiate Phase 1 clinical trialAction: Monitor regulatory progress and clinical trial site readiness for the type 1 diabetes program
- SG293 Phase 1 Clinical Trial InitiationTrigger: First-in-human dosing of SG293 in patients with non-Hodgkin lymphomaAction: Track manufacturing readiness, clinical site activation, and initial safety profiles
- Cash Runway and Capital AllocationTrigger: Cash runway dropping below 12 months of operating expensesAction: Evaluate further utilization of the at-the-market (ATM) facility or strategic partnerships to secure non-dilutive funding
Research as of 20 Jun 2026